94 assets in Chronic Myelomonocytic Leukemia

Therapeutic assets addressing Chronic Myelomonocytic Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pbsc Chronic Myelomonocytic Leukemia	Fred Hutchinson Cancer Center	P2	CCC (51)
Selinexor Chronic Myelomonocytic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (51)
E-7820 Chronic Myelomonocytic Leukemia	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
Itacitinib Chronic Myelomonocytic Leukemia	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (50)
Vedolizumab Chronic Myelomonocytic Leukemia	City of Hope Medical Center	P2	CCC (49)
Allogeneic Human Umbilical Cord Blood Chronic Myelomonocytic Leukemia	The First Affiliated Hospital with Nanjing Medical University	P1/2	CCC (48)
Bortezomib Chronic Myelomonocytic Leukemia	Indiana University	P1/2	CCC (48)
Gilteritinib Chronic Myelomonocytic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
lp-108 Chronic Myelomonocytic Leukemia	Guangzhou Lupeng Pharmaceutical Company LTD.	P1	CC (47)
s227928 Chronic Myelomonocytic Leukemia	Servier Bio-Innovation LLC	P1/2	CC (47)
prt2527 Chronic Myelomonocytic Leukemia	Prelude Therapeutics	P1	CC (46)
Zanubrutinib Chronic Myelomonocytic Leukemia	Prelude Therapeutics	P1	CC (46)
Amsacrine Chronic Myelomonocytic Leukemia	Heinrich-Heine University, Duesseldorf	P1/2	CC (43)
Anti-Clever-1 Monoclonal Antibody Fp-1305 Chronic Myelomonocytic Leukemia	Faron Pharmaceuticals Ltd	P1/2	CC (43)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 Chronic Myelomonocytic Leukemia	M.D. Anderson Cancer Center	P1	CC (43)
Apamistamab-B10-Astatine At-211 Chronic Myelomonocytic Leukemia	Fred Hutchinson Cancer Center	P1/2	CC (43)
Atezolizumab Chronic Myelomonocytic Leukemia	University of Southern California	P1/2	CC (43)
Camibirstat Chronic Myelomonocytic Leukemia	Foghorn Therapeutics Inc.	P1	CC (43)
Cbx-250 Chronic Myelomonocytic Leukemia	Crossbow Therapeutics, Inc.	P1	CC (43)
lp-118 Chronic Myelomonocytic Leukemia	Newave Pharmaceutical Inc	P1	CC (43)
LY 3410738 Chronic Myelomonocytic Leukemia	Eli Lilly and Company	P1	CC (43)
mk-0482 Chronic Myelomonocytic Leukemia	Merck Sharp & Dohme LLC	P1	CC (43)
Mobinitinib Chronic Myelomonocytic Leukemia	Ellipses Pharma	P1/2	CC (43)
nc525 Chronic Myelomonocytic Leukemia	NextCure, Inc.	P1	CC (43)
Ocifisertib Chronic Myelomonocytic Leukemia	Treadwell Therapeutics, Inc	P1/2	CC (43)
q702 Chronic Myelomonocytic Leukemia	Mayo Clinic	P1	CC (43)
rp7214 Chronic Myelomonocytic Leukemia	Rhizen Pharmaceuticals SA	P1/2	CC (43)
Sitagliptin Chronic Myelomonocytic Leukemia	Indiana University	P1/2	CC (43)
Tuspetinib Chronic Myelomonocytic Leukemia	Aptose Biosciences Inc.	P1/2	CC (43)
Bisantrene Dihydrochloride Chronic Myelomonocytic Leukemia	Racura Oncology Ltd	P1	C (39)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Chronic Myelomonocytic Leukemia	Fred Hutchinson Cancer Center	P1	C (39)
Defactinib Chronic Myelomonocytic Leukemia	Clinical Hub for Interventional Research (CHOIR)	P1	C (39)
dsp107 Chronic Myelomonocytic Leukemia	Kahr Medical	P1	C (39)
ep31670 Chronic Myelomonocytic Leukemia	Epigenetix, Inc.	P1	C (39)
Inqovi Chronic Myelomonocytic Leukemia	Massachusetts General Hospital	P1	C (39)
Olutasidenib Chronic Myelomonocytic Leukemia	City of Hope Medical Center	P1	C (39)
PRT1419 Chronic Myelomonocytic Leukemia	Prelude Therapeutics	P1	C (39)
Stx-0712 Chronic Myelomonocytic Leukemia	Solu Therapeutics, Inc	P1	C (39)
Tagraxofusp Chronic Myelomonocytic Leukemia	Karen Ballen, MD	P1	C (39)
Lilrb4 Star-T Cells Chronic Myelomonocytic Leukemia	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (30)
trx103 Chronic Myelomonocytic Leukemia	Tr1X, Inc.	P1	NR ()

Showing 51 to 94 of 94 assets

PreviousPage 2 of 2Next